Histamine-2 receptor antagonists and risk of lung cancer in diabetic patients – an exploratory analysis
Chia-Lin Hsu
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
These two authors contributed equally to this work.Search for more papers by this authorChia-Hsuin Chang
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
These two authors contributed equally to this work.Search for more papers by this authorCorresponding Author
Jou-Wei Lin
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin County, Taiwan
Correspondence to: J.-W. Lin, Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, 579 Yun-Lin Road, Section 2, Dou-Liou City, Yun-Lin County, Taiwan. E-mail: [email protected]
M.-S. Lai, Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. E-mail: [email protected]
Search for more papers by this authorLi-Chiu Wu
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorLee-Ming Chuang
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Mei-Shu Lai
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Correspondence to: J.-W. Lin, Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, 579 Yun-Lin Road, Section 2, Dou-Liou City, Yun-Lin County, Taiwan. E-mail: [email protected]
M.-S. Lai, Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. E-mail: [email protected]
Search for more papers by this authorChia-Lin Hsu
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
These two authors contributed equally to this work.Search for more papers by this authorChia-Hsuin Chang
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
These two authors contributed equally to this work.Search for more papers by this authorCorresponding Author
Jou-Wei Lin
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou City, Yun-Lin County, Taiwan
Correspondence to: J.-W. Lin, Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, 579 Yun-Lin Road, Section 2, Dou-Liou City, Yun-Lin County, Taiwan. E-mail: [email protected]
M.-S. Lai, Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. E-mail: [email protected]
Search for more papers by this authorLi-Chiu Wu
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorLee-Ming Chuang
Department of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Search for more papers by this authorCorresponding Author
Mei-Shu Lai
Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Correspondence to: J.-W. Lin, Cardiovascular Center, National Taiwan University Hospital Yun-Lin Branch, 579 Yun-Lin Road, Section 2, Dou-Liou City, Yun-Lin County, Taiwan. E-mail: [email protected]
M.-S. Lai, Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. E-mail: [email protected]
Search for more papers by this authorABSTRACT
Purpose
Histamine-2 receptor blockers (H2RBs) might have anti-tumorogenic effect, but the clinical effect on lung cancer occurrence was unclear.
Methods
A total of 640,173 type 2 diabetic patients were identified from the Taiwan National Health Insurance claims database in 2000. Patients were followed from cohort entry to the earliest of cancer diagnosis, death, disenrollment from the national health insurance, or 31 December 2007. For each participant, H2RB use during the follow-up period was ascertained from the outpatient pharmacy prescription database. Patients with incident squamous cell carcinoma (SCC) and adenocarcinoma were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Conditional logistic regression models were applied to estimate the association between H2RBs and lung cancer incidence.
Results
A total of 1182 incident SCC and 2345 adenocarcinoma cases were identified, and 13,108 matched controls were selected. An increased risk was observed for H2RBs use <1 year with adjusted OR of 1.33 (95% confidence interval (CI): 1.22–1.44). After excluding all exposures occurring in the year before lung cancer diagnosis, H2RBs use with cumulative dosage ≥ 360 “defined daily doses” was associated with a significantly decreased risk of lung cancer (OR: 0.60; 95% CI: 0.38–0.96). When we stratified on types of lung cancer, the protective association of higher cumulative use of H2RBs seemed more evident for lung adenocarcinoma, with an adjusted OR of 0.49 (95% CI: 0.26–0.90).
Conclusions
Higher cumulative use of H2RBs might be associated with a reduced risk for non-small cell lung cancer in diabetic patients. Copyright © 2013 John Wiley & Sons, Ltd.
REFERENCES
- 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
- 2 Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer 2010; 126: 1454–1466.
- 3 Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893–1907.
- 4 Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8: 773–783.
- 5 Coleman MP, Forman D, Bryant H, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011; 377: 127–138.
- 6 Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005; 294: 1505–1510.
- 7 Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25: 472–478.
- 8 Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer 2008; 113: 1012–1018.
- 9 Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829–841.
- 10 Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674–1685.
- 11 Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: E1170–E1175.
- 12 Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013; 36(1): 124–129.
- 13 Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlated with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012; 13: 143–148.
- 14 Jiang CG, Liu FR, Yu M, Li JB, Xu HM. Cimetidine induces apoptosis in gastric cancer cells in vitro and inhibits tumor growth in vivo. Oncol Rep 2010; 23: 693–700.
- 15 Tomita K, Izumi K, Okabe S. Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 2003; 93: 321–330.
- 16 Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994; 35: 1632–1636.
- 17 Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet 1995; 346: 115.
- 18 Hast R, Bernell P, Hansson M. Cimetidine as an immune response modifier. Med Oncol Tumor Pharmacother 1989; 6: 111–113.
- 19 Stoyanov E, Uddin M, Mankuta D, Dubinett SM, Levi-Schaffer F. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer 2012; 75: 38–44.
- 20 Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.
- 21 Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005; 104: 157–163.
- 22 Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011; 29: 3001–3007.
- 23 Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462–1472.
- 24 Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291–303.
- 25 Prescott E, Osler M, Hein HO, et al. Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies. Epidemiology 1998; 9: 79–83.
- 26 Yang P, Cerhan JR, Vierkant RA, et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol 2002; 156: 1114–1122.
- 27 Toyoda Y, Nakayama T, Ioka A, Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 2008; 38: 534–539.
- 28 Olsen JH, Friis S, Poulsen AH, et al. Use of NSAIDs, smoking and lung cancer risk. Br J Cancer 2008; 98: 232–237.
- 29 Slatore CG, Au DH, Littman AJ, Satia JA, White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1203–1207.
- 30 Kelly JP, Coogan P, Strom BL, Rosenberg L. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2008; 17: 322–327.
- 31 Daraselia N, Wang Y, Budoff A, et al. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2012; 2: 93–103.
- 32 Kawaguchi T, Matsumura A, Fukai S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010; 5: 1001–1010.
- 33 Shack L, Jordan C, Thomson CS, Mak V, Moller H. Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England. BMC Cancer 2008; 8: 271.
- 34 Sidorchuk A, Agardh EE, Aremu O, Hallqvist J, Allebeck P, Moradi T. Socioeconomic differences in lung cancer incidence: a systematic review and meta-analysis. Cancer Causes Control 2009; 20: 459–471.
- 35 Kim TJ, Han DH, Jin KN, Won Lee K. Lung cancer detected at cardiac CT: prevalence, clinicoradiologic features, and importance of full-field-of-view images. Radiology 2010; 255: 369–376.
- 36 Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638–642.
- 37 Kornum JB, Svaerke C, Thomsen RW, Lange P, Sorensen HT. Chronic obstructive pulmonary disease and cancer risk: A Danish nationwide cohort study. Respir Med 2012; 106: 845–852.
- 38 de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors. Am J Respir Crit Care Med 2011; 184: 913–919.
- 39 Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Bjornsson E. Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 168–174.
Citing Literature
